Neuraxpharm completed the acquisition of two product portfolios of Sanofi.

Neuraxpharm, a central nervous system specialist, completed the acquisition of two product portfolios of Sanofi, a pharmaceutical and healthcare company. Financial terms were not disclosed. "These newly acquired products not only strengthen our presence as a leading European specialty pharmaceutical company focused on CNS, but also lay the ground for further expansion of our international presence," Jörg Thomas Dierks, Neuraxpharm CEO.